Texas Attorney General Ken Paxton has launched a probe into two pharmaceutical companies that allegedly advertised and promoted puberty-blocking drugs to minors who suffer from gender dysphoria. The medications in question include Supprelin LA and Lupron Depot, which are federally approved to treat children with Central Precocious Puberty (CPP), or premature puberty. Another drug, Vantas, has been prescribed for palliative therapy for advanced prostate cancer. The U.S. Food and Drug Administration has not approved any of these drugs as treatments for gender dysphoria. Paxton’s office defines gender dysphoria as “a diagnosed mental disorder in which a person experiences significant distress related to a strong desire to be of another biological sex.” According to Paxton, his office is investigating whether Endo Pharmaceuticals Inc. and AbbVie Inc. have pushed puberty blockers for “unapproved uses without disclosing the potential risks associated with these drugs to children and their parents,” a violation of the …